Packaging and tiers for Series B companies: scaling without breaking for healthcare and life sciences in the Benelux region
How Series B companies scale packaging and tiers across regions and teams without losing the discipline that made it work at Series A. Written for commercial leaders at healthtech, medtech, and life-sciences companies in the Benelux region.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the Benelux region. In this market, Benelux buyers reward multilingual specificity and a pitch that respects local nuance, so the way you install packaging and tiers has to be shaped to that reality from day one.
Series B is the stress test for packaging and tiers. What worked at fifteen people fails at fifty unless the operating rhythm is deliberate.
The Series B move is to separate the model owner from the operators. One senior human owns strategy, average contract value by tier, and the weekly review; a small team runs the machine.
Add a second geography or segment only when the first one is producing a defensible number for two full quarters. Not before.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the Benelux region it is compounded by the fact that local nuance and language fit, not scale is what actually gates growth. Packaging and tiers is only useful here when it is pointed at both constraints at once.
Governance appears at Series B — that is fine, provided it accelerates rather than slows. The test is whether reviews still make decisions or just distribute updates.
The Series B failure mode of packaging and tiers is three tiers labelled small, medium, large that mean nothing, amplified by headcount. Fix the root cause; do not paper over it with more people.
Compensation begins to matter now. Pay operators on average contract value by tier outcomes, not on effort. Effort-based comp at Series B produces theatre.
A well-run packaging and tiers function at Series B is the moat that survives to Series C. Companies that skip this discipline burn through raises trying to buy it back.
Concretely for healthcare and life sciences in the Benelux region: the healthcare teams that install this get past procurement instead of dying in it, and one anchored Benelux customer becomes the reference the rest of the region asks for. That is the reason it is worth installing packaging and tiers deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Pricing · healthcare · Benelux — answered
- Does packaging and tiers work for healthcare and life sciences in the Benelux region?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in the Benelux region, Benelux buyers reward multilingual specificity and a pitch that respects local nuance. The healthcare teams that install this get past procurement instead of dying in it.
- How does packaging and tiers change at Series B?
- Ownership separates from execution; operating rhythm gets more deliberate; governance appears.
- When should we expand to a second region?
- After the first region delivers two straight quarters of defensible average contract value by tier.
- What compensation model works for packaging and tiers operators at Series B?
- Outcome-linked on average contract value by tier, not activity-based.
- What is the Series B stress point?
- Three tiers labelled small, medium, large that mean nothing, amplified by headcount. Fix the root, not the symptom.
- What is the Benelux-specific pitfall when running packaging and tiers for healthcare?
- Importing a playbook that was built for another market. In the Benelux region, Benelux buyers reward multilingual specificity and a pitch that respects local nuance — the install has to reflect that.
Growth Broker editorial
Filed under pricing · healthcare · benelux